From May 19 to 22, 2026, Hospitalar 2026 grandly opened in São Paulo, Brazil. As Latin America's most influential healthcare industry expo, Hospitalar gathers medical institutions, distributors, industry specialists and corporate delegates worldwide to exchange insights on cutting-edge medical technologies, innovative products and emerging industry trends.

        At this year's exhibition, LivzonDx presented a full portfolio of integrated in vitro diagnostic (IVD) solutions. Centered on full-cycle HIV diagnosis, blood safety and autoimmune testing scenarios, we displayed our latest breakthroughs in diagnostic technology innovation and complete product ecosystem to clients and partners across Brazil and Latin America.

Lively On-Site Exchanges, Exploring New Diagnostic Opportunities

        LivzonDx's booth drew a constant stream of professional visitors during the show. Our team held in-depth consultations with hospital operators, laboratory managers, distributors and institutional representatives covering critical infectious disease diagnostics (HIV, hepatitis, syphilis) and autoimmune testing.

        Through face-to-face product demos and solution briefings, LivzonDx gained deeper insights into Latin America's real market demand for high-efficiency, stable and automated diagnostic systems. We also built solid mutual trust with numerous prospective regional partners.

Multi-Scenario Diagnostic Solutions Empowering Precision Testing

        At Hospitalar 2026, LivzonDx highlighted integrated diagnostic kits and platforms covering diverse clinical and laboratory workflows, categorized into three core solution lines:

Critical Infectious Disease Diagnostic Solutions

        Targeting testing requirements for four transfusion-transmitted pathogens (HBV, HCV, HIV, syphilis) and laboratory automation, LivzonDx exhibited comprehensive molecular diagnostic systems adaptable to high- and low-throughput labs.

        Our multiplex nucleic acid assay enables simultaneous detection of HIV, HBV, HCV and other pathogens, balancing exceptional detection efficiency with superior sensitivity and accuracy. Our Quantitative Nucleic Acid Test Kit for HIV-1 stood out as a flagship exhibit. As a leading domestic HIV viral load testing solution, it adopts ready-to-use lyophilized reagents featuring easy transportation, simple operation and outstanding stability, supporting both central laboratory and near-patient point-of-care (nPOC) testing.

        For syphilis screening, we showcased the Serodia TP.PA (Passive Particle Agglutination Test for Detection of Antibodies to Treponema Pallidum). Using inert gelatin particle carriers, it delivers exceptional stability, high specificity and consistent results, widely applicable to pre-transfusion screening, preoperative testing, maternal screening and clinical syphilis confirmation.

Integrated Blood Bank Solutions

        Addressing full-lifecycle blood safety management from donors to recipients, LivzonDx showcased integrated end-to-end blood bank solutions covering core procedures including donor screening — featuring serological ELISA kits for four transfusion-transmitted pathogens (HBV, HCV, HIV-1/2 and Treponema pallidum) and multiplex nucleic acid detection kits for HIV-1/2, HBV and HCV — alongside blood grouping testing and blood irradiation systems. The portfolio enables more standardized, efficient and accessible blood safety management.

        Our X-RAD 8000 Blood Irradiator attracted wide audience attention. Powered by X-ray irradiation technology, it eliminates radioactive source management burdens and simplifies installation and routine maintenance. Supporting batch and rapid irradiation dual modes, it flexibly fits all transfusion scenarios, delivering an efficient, eco-friendly and user-friendly blood irradiation option for blood centers and hospitals.

Autoimmune Diagnostic Solutions

        LivzonDx unveiled fully automated integrated autoimmune testing platforms spanning three core technologies: Chemiluminescence Immunoassay (CLIA), multiplex DLCM technology and Indirect Immunofluorescence Assay (IFA), realizing a unified one-tube, one-stop autoimmune testing ecosystem.

        Our PATHVIZON series integrates IFA, AI, CLIA and DLCM technologies to launch the world’s first dedicated autoimmune diagnostic workflow platform. It delivers all-in-one testing covering fluorescent total antibody screening, multiplex panel detection and single-marker quantification, drastically lifting lab throughput and optimizing clinical diagnostic experience.

        For technological innovation, LivzonDx independently developed DLCM liquid-phase multiplex detection technology, enabling high-throughput multi-marker precise quantification with superior automation and quantitative performance versus traditional membrane strip assays. Our AI-powered IFA system was trained on over 200,000 fluorescence images, fully supporting the 14 mandatory ANA nuclear patterns defined by ICAP, significantly boosting automation and standardization of IFA slide interpretation.

Link the Globe via Innovation, Co-Create the Future Through Partnership

        Hospitalar 2026 serves not only as a stage to showcase our products and technologies, but also a vital platform for LivzonDx to engage global partners. This exhibition expanded our network of clients across Brazil and Latin America and strengthened our commitment to accelerated international development.

Sincere gratitude to every client, partner and industry peer who visited our booth.

Hospitalar 2026 has concluded successfully — we look forward to our next reunion!